- BioNTech has completed its acquisition of Biotheus for $800 million, with additional performance-based payments of up to $150 million.
- The deal grants BioNTech full rights to BNT327 and Biotheus’ antibody generation platform, expanding its oncology capabilities and China presence.
BioNTech SE has finalised its acquisition of Biotheus, a clinical-stage biotechnology company focused on novel antibody development for oncology and inflammatory diseases. The transaction, initially announced in November 2024, enhances BioNTech’s research and development capabilities, particularly in bispecific antibodies.
The acquisition builds on BioNTech’s collaboration with Biotheus on BNT327, a late-stage bispecific antibody targeting PD-L1 and VEGF-A. With this deal, BioNTech now holds full global rights to BNT327 and other candidates from Biotheus’ pipeline. Additionally, BioNTech gains access to Biotheus’ antibody generation platform and bispecific antibody-drug conjugate capabilities.
Biotheus will continue operations as an indirect Chinese subsidiary of BioNTech, contributing a local research and development hub and an advanced biologics manufacturing facility to BioNTech’s network. The acquisition aligns with BioNTech’s oncology strategy, supporting its aim to develop BNT327 as a pan-tumour technology platform for combination therapies.
The total consideration for the acquisition is $800 million, primarily in cash, with a small portion in BioNTech American Depositary Shares. The agreement also includes up to $150 million in performance-based payments if specific milestones are achieved.